Heterogeneity in Breast cancer

Breast cancer is malignant tumor occurred on breast epithelial tissue, although the mortality rate of breast cancer decreases, it remains one of the highest mortality rate diseases. Ignoring few exceptions, almost all tumors are derived from one single cancer cell. However, in clinical diagnosis, most human tumors demonstrate amazing heterogeneity in many morphological and physical characteristics. At the molecular level, human breast cancer is a complex heterogeneous disease in natural history. The combination of molecular origin and malignant cells and the diversity of hosting environment created the tumor subpopulations, which have different phenotypic characteristics. These subpopulations have different responses to the treatment and clinical outcomes. According to the combined affection of genetic and epigenetic instability and therapeutic interventions, different evolutionary routes will be generated thereby caused the inevitable tumor heterogeneity. In this review, the heterogeneous indication of genetic and epigenetic and metastatic as well as the potential causes and their effect for the clinical management of breast cancer were discussed.

[1]  S. Rashid,et al.  Hallmarks of Cancer Cell , 2017 .

[2]  K. Wani,et al.  Mutational analysis of the BRCA2 gene in breast carcinoma patients of Kashmiri descent. , 2014, Molecular medicine reports.

[3]  Jicheng Li,et al.  BRCA1 Germ‐Line Mutations and Tumor Characteristics in Eastern Chinese Women with Familial Breast Cancer , 2013, Anatomical record.

[4]  Y. Bignon,et al.  Mutation Screening of the BRCA1 Gene in Early Onset and Familial Breast/Ovarian Cancer in Moroccan Population , 2012, International journal of medical sciences.

[5]  T. Spector,et al.  DNA methylation profiling in breast cancer discordant identical twins identifies DOK7 as novel epigenetic biomarker , 2012, Carcinogenesis.

[6]  Tae-Young Roh,et al.  Characterization of Chromatin Structure-associated Histone Modifications in Breast Cancer Cells , 2012, Genomics & informatics.

[7]  F. Pajonk,et al.  Radiation‐Induced Reprogramming of Breast Cancer Cells , 2012, Stem cells.

[8]  M. Wicha,et al.  Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia , 2012, Proceedings of the National Academy of Sciences.

[9]  M. Wei,et al.  Promoter methylation status and expression of estrogen receptor alpha in familial breast cancer patients , 2012, Tumor Biology.

[10]  R. Gelber,et al.  Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  M. J. van de Vijver,et al.  An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  A. Pietras Cancer stem cells in tumor heterogeneity. , 2011, Advances in cancer research.

[13]  Karen Gelmon,et al.  Metastatic behavior of breast cancer subtypes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Helena R. Chang,et al.  Trastuzumab‐based neoadjuvant therapy in patients with HER2‐positive breast cancer , 2010, Cancer.

[15]  A. Di Donna Antiangiogenic agents. , 2010, Current pharmaceutical design.

[16]  K. Polyak,et al.  Tumor heterogeneity: causes and consequences. , 2010, Biochimica et biophysica acta.

[17]  F. Esteva,et al.  Survival among women with triple receptor-negative breast cancer and brain metastases. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  Tara L. Naylor,et al.  Estrogen Receptor Status Could Modulate the Genomic Pattern in Familial and Sporadic Breast Cancer , 2007, Clinical Cancer Research.

[19]  Kornelia Polyak,et al.  Breast Tumor Heterogeneity: Cancer Stem Cells or Clonal Evolution? , 2007, Cell cycle.

[20]  J. Andersen,et al.  Intratumor genomic heterogeneity in breast cancer with clonal divergence between primary carcinomas and lymph node metastases , 2007, Breast Cancer Research and Treatment.

[21]  J. Mackey,et al.  Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Peterse,et al.  Breast cancer metastasis: markers and models , 2005, Nature Reviews Cancer.

[23]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[24]  T. Ørntoft,et al.  DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis , 2005, Nature.

[25]  C. Osborne,et al.  Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu , 1992, Breast Cancer Research and Treatment.

[26]  M. Nowak,et al.  Dynamics of cancer progression , 2004, Nature Reviews Cancer.

[27]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[28]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[29]  A. Schäffer,et al.  Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. , 1997, Cancer research.

[30]  P. Nowell The clonal evolution of tumor cell populations. , 1976, Science.